Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) is projected to post its results before the market opens on Friday, August 7th. Analysts expect the company to announce earnings of ($0.2471) per share for the quarter.
Jasper Therapeutics Stock Performance
JSPRW stock opened at $0.01 on Wednesday. Jasper Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.15. The stock’s 50 day moving average is $0.01 and its 200-day moving average is $0.02.
About Jasper Therapeutics
Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.
The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.
Recommended Stories
- Five stocks we like better than Jasper Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
